210 related articles for article (PubMed ID: 34193246)
1. A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer.
Ylitalo EB; Thysell E; Landfors M; Brattsand M; Jernberg E; Crnalic S; Widmark A; Hultdin M; Bergh A; Degerman S; Wikström P
Clin Epigenetics; 2021 Jun; 13(1):133. PubMed ID: 34193246
[TBL] [Abstract][Full Text] [Related]
2. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival.
Hörnberg E; Ylitalo EB; Crnalic S; Antti H; Stattin P; Widmark A; Bergh A; Wikström P
PLoS One; 2011 Apr; 6(4):e19059. PubMed ID: 21552559
[TBL] [Abstract][Full Text] [Related]
3. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response.
Ylitalo EB; Thysell E; Jernberg E; Lundholm M; Crnalic S; Egevad L; Stattin P; Widmark A; Bergh A; Wikström P
Eur Urol; 2017 May; 71(5):776-787. PubMed ID: 27497761
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiles define molecular subtypes of prostate cancer bone metastases with different outcomes and morphology traceable back to the primary tumor.
Thysell E; Vidman L; Ylitalo EB; Jernberg E; Crnalic S; Iglesias-Gato D; Flores-Morales A; Stattin P; Egevad L; Widmark A; Rydén P; Bergh A; Wikström P
Mol Oncol; 2019 Aug; 13(8):1763-1777. PubMed ID: 31162796
[TBL] [Abstract][Full Text] [Related]
5. Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity.
Nordstrand A; Bovinder Ylitalo E; Thysell E; Jernberg E; Crnalic S; Widmark A; Bergh A; Lerner UH; Wikström P
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670000
[TBL] [Abstract][Full Text] [Related]
6. Characterization of prostate cancer bone metastases according to expression levels of steroidogenic enzymes and androgen receptor splice variants.
Jernberg E; Thysell E; Bovinder Ylitalo E; Rudolfsson S; Crnalic S; Widmark A; Bergh A; Wikström P
PLoS One; 2013; 8(11):e77407. PubMed ID: 24244276
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT
Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases.
Zhang X; Morrissey C; Sun S; Ketchandji M; Nelson PS; True LD; Vakar-Lopez F; Vessella RL; Plymate SR
PLoS One; 2011; 6(11):e27970. PubMed ID: 22114732
[TBL] [Abstract][Full Text] [Related]
9. Clinical and biological relevance of the transcriptomic-based prostate cancer metastasis subtypes MetA-C.
Thysell E; Köhn L; Semenas J; Järemo H; Freyhult E; Lundholm M; Thellenberg Karlsson C; Damber JE; Widmark A; Crnalic S; Josefsson A; Welén K; Nilsson RJA; Bergh A; Wikström P
Mol Oncol; 2022 Feb; 16(4):846-859. PubMed ID: 34889043
[TBL] [Abstract][Full Text] [Related]
10. Nuclear androgen receptor staining in bone metastases is related to a poor outcome in prostate cancer patients.
Crnalic S; Hörnberg E; Wikström P; Lerner UH; Tieva A; Svensson O; Widmark A; Bergh A
Endocr Relat Cancer; 2010 Dec; 17(4):885-95. PubMed ID: 20688881
[TBL] [Abstract][Full Text] [Related]
11. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
Chung C; Abboud K
Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP.
Karpf AR; Bai S; James SR; Mohler JL; Wilson EM
Mol Cancer Res; 2009 Apr; 7(4):523-35. PubMed ID: 19372581
[TBL] [Abstract][Full Text] [Related]
13. Cell-by-cell quantification of the androgen receptor in benign and malignant prostate leads to a better understanding of changes linked to cancer initiation and progression.
Derderian S; Benidir T; Scarlata E; Altaylouni T; Hamel L; Zouanat FZ; Brimo F; Aprikian A; Chevalier S
J Pathol Clin Res; 2023 Jul; 9(4):285-301. PubMed ID: 37073437
[TBL] [Abstract][Full Text] [Related]
14. Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential.
Miller ET; You S; Cadaneanu RM; Kim M; Yoon J; Liu ST; Li X; Kwan L; Hodge J; Quist MJ; Grasso CS; Lewis MS; Knudsen BS; Freeman MR; Garraway IP
BMC Cancer; 2020 May; 20(1):398. PubMed ID: 32380981
[TBL] [Abstract][Full Text] [Related]
15. High levels of the AR-V7 Splice Variant and Co-Amplification of the Golgi Protein Coding YIPF6 in AR Amplified Prostate Cancer Bone Metastases.
Djusberg E; Jernberg E; Thysell E; Golovleva I; Lundberg P; Crnalic S; Widmark A; Bergh A; Brattsand M; Wikström P
Prostate; 2017 May; 77(6):625-638. PubMed ID: 28144969
[TBL] [Abstract][Full Text] [Related]
16. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A
Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789
[TBL] [Abstract][Full Text] [Related]
17. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
Linder A; Larsson K; Welén K; Damber JE
Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
[TBL] [Abstract][Full Text] [Related]
18. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
[TBL] [Abstract][Full Text] [Related]
19. Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes.
Olsen JR; Azeem W; Hellem MR; Marvyin K; Hua Y; Qu Y; Li L; Lin B; Ke X; Øyan AM; Kalland K
BMC Cancer; 2016 Jul; 16():377. PubMed ID: 27378372
[TBL] [Abstract][Full Text] [Related]
20. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer.
Zhao N; Peacock SO; Lo CH; Heidman LM; Rice MA; Fahrenholtz CD; Greene AM; Magani F; Copello VA; Martinez MJ; Zhang Y; Daaka Y; Lynch CC; Burnstein KL
Sci Transl Med; 2019 Jun; 11(498):. PubMed ID: 31243151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]